← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $255B	2,490	+125	+5%	$182B
2	2 Danaher DHR $161B	2,132	+42	+2%	$137B
3	3 Regeneron Pharmaceuticals REGN $82.7B	1,273	+96	+8%	$80.8B
4	4 Novartis NVS $288B	1,272	+50	+4%	$14.3B
5	5 Agilent Technologies A $49.3B	1,005	+86	+9%	$35.7B
6	6 Illumina ILMN $40.2B	811	-7	-0.9%	$20B
7	7 Charles River Laboratories CRL $14.6B	634	+13	+2%	$12.3B
8	8 Alnylam Pharmaceuticals ALNY $31.1B	499	+46	+10%	$22.4B
9	9 Revvity RVTY $17.2B	489	-16	-3%	$11.7B
10	10 CRISPR Therapeutics CRSP $4.96B	470	+65	+16%	$3.48B
11	11 DELISTED CATALENT, INC. CTLT	424	-10	-2%	$8.9B
12	12 Sarepta Therapeutics SRPT $1.89B	396	+1	+0.3%	$7.92B
13	13 Ionis Pharmaceuticals IONS $7.33B	363	+53	+17%	$7.21B
14	14 Bruker BRKR $8.54B	360	+15	+4%	$8.05B
15	15 Ginkgo Bioworks DNA $772M	342	-6	-2%	$2.14B
16	16 Azenta AZTA $1.6B	319	+10	+3%	$3.81B
17	17 ARK Genomic Revolution ETF ARKG $2.07B	300	+12	+4%	$619M
18	18 Guardant Health GH $22.2B	295	-1	-0.3%	$2.99B
19	19 Intellia Therapeutics NTLA $1.62B	293	+8	+3%	$2.6B
20	20 Qiagen QGEN $9.57B	278	0	0%	$6.15B
21	21 10x Genomics TXG $9.32B	275	+19	+7%	$5.37B
22	22 Pacific Biosciences PACB $609M	274	+1	+0.4%	$2.76B
23	23 Arrowhead Research ARWR $8.29B	266	+11	+4%	$2.38B
24	24 Veracyte VCYT $3.62B	250	+14	+6%	$2.13B
25	25 BridgeBio Pharma BBIO $13.2B	247	+27	+12%	$6.69B